What if every person with lupus underwent simple and noninvasive testing to track abnormal hardening in the coronary arteries—so that something could be done right away if a problem were found?

Joan Von Feldt, MD
University of Pennsylvania, Philadelphia, PA
Clinical Trials Initiative Grant
Class of 2002

The presence of antiphospholipid antibodies dramatically raises the risk for blood clots, heart attack, stroke, and miscarriage in about a third of people with lupus. But which should get aggressive treatment to prevent problems?

Robert A. S. Roubey, MD
University of North Carolina at Chapel Hill, NC
Class of 2004

Could a therapy to prevent the rapid death and slow replacement of endothelial cells that line the heart’s blood vessels slash the risk for premature atherosclerosis in lupus?

Mariana J. Kaplan, MD
University of Michigan, Ann Arbor, MI
Class of 2002

How about spotting and stopping premature hardening and clogging of vessels early on—before a heart attack or stroke signals a problem?

Robert M. Clancy, PhD
New York University School of Medicine, New York, NY
Class of 2003/2004

Robert A. Eisenberg, MD
University of Pennsylvania School of Medicine, Philadelphia, PA
2006 Imaging
Class of 2002

Amy S. Major, PhD
Vanderbilt University School of Medicine, Nashville, TN
Class of 2005

Could a certain form of the normally “good” HDL cholesterol actually be to blame?

Bevra Hahn, MD
University of California at Los Angeles, CA
Class of 2003/2004

Steven Bensinger, VMD, PhD
University of California, Los Angeles, CA
Class of 2009

Natalia Beglova, PhD
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
Class of 2011

Mariana J. Kaplan, MD
University of Michigan, Ann Arbor, MI
Class of 2012